Upper Tract Urothelial Carcinoma (UTUC) Overview
Learn About Upper Tract Urothelial Carcinoma (UTUC)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Mskcc Surgery Group
Guido Dalbagni is an Urologist in New York, New York. Dr. Dalbagni is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.
Regents Of The University Of California
Ithaar Derweesh is an Urologist in San Diego, California. Dr. Derweesh is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Renal Cell Carcinoma (RCC), Upper Tract Urothelial Carcinoma (UTUC), Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery.
Henry Ford Health System
Firas Abdollah is an Urologist in Detroit, Michigan. Dr. Abdollah is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Prostate Cancer, Urothelial Cancer, Prostatectomy, and Nephrectomy. Dr. Abdollah is currently accepting new patients.
Summary: In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic e...
Summary: The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.